Drug Profile
Research programme: vancomycin nanoparticles - AlphaRx
Alternative Names: Vancomycin nanoparticles; VansolinLatest Information Update: 23 Sep 2011
Price :
$50
*
At a glance
- Originator AlphaRx
- Class Glycopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nosocomial pneumonia; Sepsis
Most Recent Events
- 18 Feb 2010 Preclinical development is ongoing
- 27 May 2008 AlphaRx establishes CRADA with US Army for the development of antibacterial nanoparticles in severe intracellular bacterial infections
- 12 Nov 2007 Preclinical data added to the pharmacokinetics and Bacterial Infections pharmacodynamics sections